Shares of Marksans Pharma surged over 8 per cent on Tuesday after the company acquired US-based Time-Cap Laboratories for an undisclosed amount.
The stock climbed 8.43 per cent to Rs 63.71 on BSE. On NSE, it jumped 7.76 per cent to Rs 63.70.
The acquisition was done through its wholly-owned subsidiary, Marksans Pharma. With this move, the company is strategically increasing its presence in the US market, the largest pharmaceutical market in the world, Marksans Pharma said in a filing to BSE.
New York-based Time-Cap is a manufacturer and marketer of solid dose generic pharmaceuticals, including private label over-the-counter medications, generic prescription drugs and nutritional supplements, it said today.
The company manufactures over 50 unique products from its New York facility, including tablets, capsules and pellets.
Union Budget 2026: Can India put its AI ambitions on fast track?
'If we don't, Russia or China will': Trump doubles down on takeover of Greenland
State Street to acquire 23% stake in Groww AMC to expand India-focused investment offerings
Infosys ADRs rise 2% in pre-market session as FY26 guidance raised
One ticket, smoother travel: Saudia and Air India ink codeshare deal for India–Saudi routes
Fake Silver In Memento For Retired Railway Employees Triggers Probe
Rajnath Singh Salutes Armed Forces Veterans, Calls Them India’s Greatest Strength
Silver Rally Turns Explosive: $100 Crossed, $115 Next?
Denmark Backs Aravalli Restoration Study, Calls Land Degradation A Global Climate Challenge
Tata Elxsi Q3 Results: Profit Slides, Stock Under Pressure Despite Margin Recovery
FirstCry shares hit 52-week low; down nearly 30% in six months; what's next?
Groww stock rises despite Q3 profit drop; analysts share outlook
RBI gives nod to Japan's SMBC to set up subsidiary in India; what it means for YES BankInfosys ADRs rise 2% in pre-market session as FY26 guidance raised
Labour Codes impact: Infosys Q3 provisions at Rs 1,289 cr; top 3 IT firms at Rs 4,373 cr